Table 4.
Association of body composition categories with all-cause mortality in 11,616 participants of NHANES 1999–2004∗
| Mortality status through 2011 | ||||
|---|---|---|---|---|
| Body composition | HR (95% CI) |
|||
| Model 1 | Model 2 | Model 3 | Model 4 | |
| Entire cohort (n = 11,616) | ||||
| Nonsarcopenic nonobese | Reference | Reference | Reference | Reference |
| Sarcopenic | 2.72 (2.25–3.29) | 1.62 (1.33–1.99) | 1.35 (1.10–1.67) | 1.32 (1.06–1.66) |
| Obese | 2.09 (1.74–2.50) | 1.27 (1.05–1.52) | 1.09 (0.90–1.32) | 0.98 (0.81–1.18) |
| Sarcopenic-obese | 6.99 (5.65–8.65) | 1.69 (1.38–2.06) | 1.35 (1.09–1.66) | 1.28 (1.04–1.57) |
| Participants with eGFR ≥60 ml/min/1.73 m2 (n = 10,515) | ||||
| Nonsarcopenic nonobese | Reference | Reference | Reference | Reference |
| Sarcopenic | 2.80 (2.14–3.66) | 1.79 (1.37–2.35) | 1.44 (1.07–1.93) | 1.45 (1.07–1.97) |
| Obese | 2.24 (1.78–2.81) | 1.41 (1.12–1.77) | 1.21 (0.96–1.54) | 1.09 (0.87–1.37) |
| Sarcopenic-obese | 7.45 (5.65–9.82) | 2.09 (1.61–2.70) | 1.64 (1.26–2.13) | 1.57 (1.19–2.05) |
| Participants with eGFR <60 ml/min/1.73 m2 (n = 1101) | ||||
| Nonsarcopenic nonobese | Reference | Reference | Reference | Reference |
| Sarcopenic | 1.79 (1.32–2.44) | 1.46 (1.06–2.02) | 1.24 (0.89–1.71) | 1.14 (0.80–1.64) |
| Obese | 0.93 (0.72–1.19) | 1.00 (0.77–1.30) | 0.87 (0.67–1.12) | 0.77 (0.59–1.01) |
| Sarcopenic-obese | 1.83 (1.34–2.48) | 1.19 (0.88–1.62) | 1.05 (0.75–1.46) | 0.97 (0.70–1.35) |
| Mortality status through 2006 | ||||
|---|---|---|---|---|
| Body composition | HR (95% CI) |
|||
| Model 1 | Model 2 | Model 3 | Model 4 | |
| Entire cohort (n = 11,616) | ||||
| Nonsarcopenic nonobese | Reference | Reference | Reference | Reference |
| Sarcopenic | 2.99 (2.34–3.83) | 1.68 (1.29–2.19) | 1.39 (1.03–1.87) | 1.34 (1.00–1.83) |
| Obese | 1.93 (1.51–2.47) | 1.18 (0.92–1.50) | 1.00 (0.77–1.28) | 0.86 (0.67–1.12) |
| Sarcopenic-obese | 7.14 (5.43–9.40) | 1.65 (1.18–2.30) | 1.23 (0.83–1.84) | 1.17 (0.81–1.70) |
| Participants with eGFR ≥60 ml/min/1.73 m2 (n = 10,515) | ||||
| Nonsarcopenic nonobese | Reference | Reference | Reference | Reference |
| Sarcopenic | 3.13 (2.20–4.48) | 1.95 (1.38–2.75) | 1.52 (1.02–2.26) | 1.51 (1.00–2.30) |
| Obese | 2.11 (1.53–2.90) | 1.34 (0.97–1.85) | 1.15 (0.83–1.60) | 1.00 (0.71–1.40) |
| Sarcopenic-obese | 8.26 (5.51–12.38) | 2.30 (1.42–3.72) | 1.75 (1.07–2.87) | 1.63 (1.02–2.61) |
| Participants with eGFR <60 ml/min/1.73 m2 (n = 1101) | ||||
| Nonobese nonsarcopenic | Reference | Reference | Reference | Reference |
| Sarcopenic | 1.79 (1.17–2.74) | 1.38 (0.87–2.18) | 1.24 (0.80–1.90) | 1.16 (0.74–1.81) |
| Obese | 0.87 (0.62–1.24) | 0.94 (0.68–1.29) | 0.77 (0.55–1.07) | 0.67 (0.47–0.95) |
| Sarcopenic-obese | 1.61 (1.03–2.50) | 0.95 (0.57–1.58) | 0.77 (0.48–1.23) | 0.73 (0.46–1.17) |
Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity. Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, and log-transformed urine albumin-creatinine ratio. Model 4: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than nonmelanoma skin cancer), eGFR categories, log-transformed urine albumin−creatinine ratio, serum albumin, log-transformed C-reactive protein. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NHANES, National Health and Nutrition Examination Survey.
P value for interaction by CKD status: mortality through 2011, P = 0.01; mortality status through 2006, P = 0.01. Boldface values indicate P < 0.05.